Note: This document contains side effect information about didanosine. Some of the dosage forms listed on this page may not apply to the brand name Videx EC.
More frequent side effects include: pancreatitis. See below for a comprehensive list of adverse effects.
Applies to didanosine: oral capsule delayed release, oral powder for suspension
Oral route (Capsule, Delayed Release; Powder for Solution)
Warning: Pancreatitis, Lactic Acidosis and Hepatomegaly with SteatosisFatal and nonfatal pancreatitis has occurred during therapy with didanosine used alone or in combination regimens in both treatment-naive and treatment-experienced patients, regardless of degree of immunosuppression. Didanosine should be suspended in patients with suspected pancreatitis and discontinued in patients with confirmed pancreatitis.Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including didanosine and other antiretrovirals. Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other antiretroviral agents.Coadministration of didanosine and stavudine is contraindicated because of increased risk of serious and/or life-threatening events. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occurs
Along with its needed effects, didanosine (the active ingredient contained in Videx EC) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking didanosine:
Incidence not known
Some side effects of didanosine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to didanosine: oral delayed release capsule, oral powder for reconstitution, oral tablet chewable
The most common side effects were diarrhea, peripheral neurologic symptoms/neuropathy, abdominal pain, nausea, headache, rash, and vomiting. Significant toxicities included pancreatitis, lactic acidosis/severe hepatomegaly with steatosis, retinal changes, optical neuritis, and peripheral neuropathy.
Very common (10% or more): Diarrhea (up to 70%), nausea (up to 53%), elevated amylase (up to 31%), vomiting (up to 30%), elevated lipase (up to 26%), abdominal pain (up to 13%)
Common (1% to 10%): Pancreatitis
Postmarketing reports: Dyspepsia, flatulence, pancreatitis (including fatal cases), dry mouth, sialoadenitis, parotid gland enlargement, increased/abnormal serum amylase
In combination therapy trials, elevated amylase (grades 3 to 4: up to 8%; all grades: up to 31%) and lipase (grades 3 to 4: up to 7%; all grades: up to 26%) were reported; grades 3 to 4 amylase and lipase elevations were greater than 2 times the upper limit of normal (2 x ULN).
In monotherapy trials, elevated amylase (at least 1.4 x ULN) was reported in up to 17% of patients.
Pancreatitis resulting in death has been reported during clinical trials of this drug in combination with other antiretroviral agents. The frequency of pancreatitis was dose-related. In phase 3 trials with buffered formulations, incidence ranged from 1% to 10% with doses higher than currently recommended and 1% to 7% with recommended doses.
In combination therapy trials, elevated AST (grades 3 to 4: up to 7%; all grades: up to 53%), ALT (grades 3 to 4: up to 8%; all grades: up to 50%), bilirubin (grades 3 to 4: up to 16%; all grades: up to 68%), and GGT (grades 3 to 4: up to 5%; all grades: up to 28%) were reported; grades 3 to 4 AST, ALT, and GGT elevations were greater than 5 x ULN and grades 3 to 4 bilirubin elevations were greater than 2.6 x ULN.
In monotherapy trials, elevated AST (greater than 5 x ULN) and ALT (greater than 5 x ULN) were each reported in up to 9% of patients.
Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals.
Fatal hepatic events were reported most often in patients treated with this drug in combination with hydroxyurea and stavudine.
Very common (10% or more): Elevated bilirubin (up to 68%), elevated AST (up to 53%), elevated ALT (up to 50%), elevated GGT (up to 28%)
Frequency not reported: Severe hepatomegaly with steatosis, hepatic toxicity, fatal hepatic events, fulminant hepatitis (including fatal cases)
Postmarketing reports: Hepatic steatosis, noncirrhotic portal hypertension, hepatitis, liver failure
Neuropathy presented as tingling, numbness, or pain in the hands or soles of the feet which progressed up the legs. The incidence was higher in patients with history of neuropathy and/or low CD4+ cell counts (less than 50 cells/mm3). Following discontinuation of this drug, neuropathy usually resolved within 2 to 12 weeks.
Very common (10% or more): Headache (up to 46%), peripheral neurologic symptoms/neuropathy (up to 26%)
Frequency not reported: Seizures
Very common (10% or more): Rash (up to 30%)
Common (1% to 10%): Rash/pruritus
Frequency not reported: Lipoatrophy/subcutaneous fat loss, cutaneous leukocytoclastic vasculitis
Postmarketing reports: Alopecia
Subcutaneous fat loss was most apparent in the face, limbs, and buttocks. The incidence and severity of lipoatrophy have been linked to cumulative exposure. Often, lipoatrophy was not reversible when this drug was discontinued.
In monotherapy trials, elevated alkaline phosphatase (greater than 5 x ULN) was reported in up to 4% of patients.
Common (1% to 10%): Fatigue
Uncommon (0.1% to 1%): Increased alkaline phosphatase
Frequency not reported: Edema
Postmarketing reports: Asthenia, chills/fever, pain, increased/abnormal alkaline phosphatase
-Frequency not reported: Increased weight, increased blood lipid levels
Common (1% to 10%): Neutropenia
Uncommon (0.1% to 1%): Anemia, thrombocytopenia
Frequency not reported: Splenomegaly
Postmarketing reports: Leukopenia, granulocytopenia
Thrombocytopenia and splenomegaly have been reported as early signs of noncirrhotic portal hypertension.
Anemia and thrombocytopenia have also been reported during postmarketing experience.
Common (1% to 10%): Elevated serum uric acid
Frequency not reported: Hyperuricemia, hypertriglyceridemia, impaired glucose tolerance, insulin-dependent diabetes mellitus, acute gouty arthritis
Postmarketing reports: Anorexia, symptomatic hyperlactatemia/lactic acidosis, diabetes mellitus, hypoglycemia, hyperglycemia
-Frequency not reported: Increased glucose levels
In monotherapy trials, elevated uric acid (greater than 12 mg/dL) was reported in up to 3% of patients.
Hyperlactatemia appeared to be more common with this drug while lactic acidosis was an infrequent occurrence.
Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals. Fatal lactic acidosis has been reported in pregnant women who received this drug plus stavudine with other antiretroviral agents.
In a report following patients on combined therapy with this drug and tenofovir, 1 patient developed didanosine-related toxicity characterized by lactic acidosis with liver failure after 3 months using 200 mg/day of this drug with tenofovir.
In 1 case report, acute gouty arthritis developed 14 weeks after this drug was added to the treatment regimen of a patient receiving ritonavir, both known to infrequently cause hyperuricemia. The symptoms resolved upon discontinuation of this drug and a short course of indomethacin.
Frequency not reported: Insomnia, restlessness
Frequency not reported: Retinal changes, optic neuritis, diffuse dysfunction of the retinal epithelium with bilateral visual deficit (including night blindness and a peripheral visual fold reduction)
Postmarketing reports: Dry eyes, retinal depigmentation
Diffuse dysfunction of the retinal epithelium has been reported in 2 patients during therapy with this drug. Both patients experienced bilateral visual deficit including night blindness and a peripheral visual fold reduction. Symptoms were first noted after 31 and 34 weeks of therapy. Deficits in both patients appeared to be partially reversible upon discontinuation of this drug.
Optic neuritis has also been reported during postmarketing experience.
Frequency not reported: Osteonecrosis
Postmarketing reports: Myalgia (with or without increased creatine phosphokinase), rhabdomyolysis (including acute renal failure and hemodialysis), arthralgia, myopathy, increased/abnormal creatine phosphokinase
Postmarketing reports: Anaphylactoid/anaphylactic reaction
Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)
Postmarketing reports: Gynecomastia
Frequency not reported: Dyspnea, orthopnea
Frequency not reported: Cardiomyopathy aggravated, pericarditis, left ventricular failure
Underlying cardiomyopathy may have been aggravated by treatment with buffered formulations, which had high sodium content.
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Videx Ec